With a median follow-up of 9.2 yr , patients > 70 yr had a shorter time to progression ( p = 0.028 ) , overall survival ( p < 0.001 ) , and NMIBC-specific survival ( p = 0.049 ) after adjustment for EORTC risk scores in the multivariate analysis .